Markets

KaloBios (KBIO) is now in Oversold Territory - Tale of the Tape

KaloBios Pharmaceuticals Inc's ( KBIO ) share price has entered into oversold territory with an RSI value of 24.4. The Zacks Consensus Estimate for KaloBios for the full year period has improved 8 cents over the past two months to -$1.40 per share. Currently, KaloBios has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( KBIO ) after its recent drop.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

KALOBIOS PHARMA (KBIO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More